Gerresheimer achieves record earnings for the financial year 2010

Dusseldorf (ots) -

- Cross-reference: Press release including Group Key Figures is
available at http://www.presseportal.de/dokumente abrufbar -

- Group revenues rise by 5.6% on a like-for-like basis in the
financial year 2010 to EUR 1024.8m
- Adjusted EBITDA margin reaches 20.0% compared with 19.2% in the
prior year
- Net income at new high of EUR 46.7m following EUR 7.0m in the
prior year
- Net financial debt cut by EUR 62.3m
- Dividend proposal: EUR 0.50 per share

Gerresheimer AG, one of the leading worldwide suppliers to the
pharma and healthcare industry, finished the financial year 2010 with
record results. "The financial year 2010 was very successful for us.
Our know-how and products are very much in demand from international
pharma customers. Our shareholders should participate in this
success. We therefore propose to the Annual General Meeting a
dividend of EUR 0.50 per share", says Uwe Röhrhoff, CEO of
Gerresheimer AG.

Gerresheimer achieved a marked increase in revenues in the
financial year 2010 (December 1, 2009 to November 30, 2010).
Excluding the Technical Plastic Systems business, which was sold in
2009, revenues grew by 5.6% to EUR 1024.8m. At constant exchange
rates, revenues grew by 4.0%. The main growth contributors in the
pharma business were insulin pens, inhalers, vials, ampoules and
prefillable syringes. Demand for cosmetics packaging revived markedly
in 2010. The market for life science research products also
recovered.

Gerresheimer increased its Adjusted EBITDA to EUR 204.5m in 2010.
This was 10.0% up on the prior year. The Adjusted EBITDA margin was
further improved on a like-for-like basis by 0.8 percentage points on
the prior year to 20.0%. Net income reached a record level at EUR
46.7m (prior year EUR 7.0m). Adjusted earnings per share also
improved significantly from EUR 1.34 to EUR 1.95.

The marked improvement in operating results also had a positive
effect on cash flow. A total of EUR 62.3m was applied to further debt
repayments. Net financial debt at the end of the year was therefore
at the historically low level of EUR 311.0m.

"In 2010 we achieved our targets and even exceeded some of them.
In the coming years we will further expand our position as a full
service provider in the important growth markets such as diabetes and
generics for example. In doing so the emerging countries play an
increasing role. We want to grow our revenues substantially in these
markets, and to double them by 2013 to EUR 200m", Röhrhoff says.

Outlook

For the financial year 2011 Gerresheimer assumes further revenue
growth of 3% to 4% at constant exchange rates. This is equivalent to
nominal revenue growth of 4% to 5%. With regard to the EBITDA margin
the company assumes a level of around 20%. In 2011 the company
expects to invest around EUR 80m. The Management Board proposes to
the General Meeting a dividend payment of EUR 0.50 per share for the
financial year 2010.

The Annual Report and for the first time also the Online Annual
Report can be found under: http://annualreport2010.gerresheimer.com

Pressekontakt:
Gerresheimer AG
Benrather Strasse 18 - 20
40213 Düsseldorf Germany

Jens Kürten
Director Corporate Communication & Marketing
Telephone +49 211 6181-250
Telefax +49 211 6181-241
E-Mail j.kuerten@gerresheimer.com
Internet www.gerresheimer.com